Pharmaline has been acquired by Gilde Healthcare Partners
The private shareholders of Pharmaline have sold 55% of their share capital to Gilde Healthcare Partners for an undisclosed consideration.
Pharmaline is specialized in the semi-industrial manufacturing of unregistered pharmacy preparation products. Pharmaline's facilities and production processes are structured to comply with the guidelines of the Dutch Health Care Inspectorate and the Good Manufacturing Practice guidelines, which have been mandatory for a pharmacy preparation production company since 2007. Pharmaline services the Dutch intramural (hospital pharmacies) and extramural (public pharmacies and general practitioner’s pharmacies) pharmacy markets.
Gilde Healthcare Partners is a European venture capital and growth capital firm. The funds focus on companies engaged in the development of novel therapeutics, diagnostics, medical devices and healthcare services.
Oaklins' team in the Netherlands acted as advisor to the seller in this transaction.
Talk to the deal team
Related deals
Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard
Bluegem Capital Partners and AREV Partners have successfully completed the acquisition of the prestigious Groupe Pinard from IK Partners.
Learn moreLumiforte partners with Kartesia to propel global growth and innovation
Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more